Apotex, a Canadian manufacturer of generics, recently introduced APO-Apixaban tablets, Canada's first generic alternative to Bristol-Myers Squibb’s Eliquis.
Apotex's apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots. Available in 2.5 mg and 5mg tablets, the product comes in multiple package sizes including 60, 180 and 500 btl.
“It is with great pride that we launch APO-Apixaban,” said Raymond Shelley, senior vice president of commercial operations, Canada and rest of world markets. “Gaining access to a generic option of an important medication like Eliquis provides patients with more affordable opportunities for the treatment of blood clots.”
Anticoagulants, also known as blood thinners, are administered to patients who are at a high risk of getting blood clots to reduce their chances of developing serious conditions such as strokes and heart attacks. APO-Apixaban adds to Apotex’s anticoagulant portfolio, which currently includes APO-Dabigatran.